Physician profile
Amber Stern
NPI 1861047672
$2,660.96
in general payments reported to CMS, 2019-2025
21 companies · $647 in 2025
The $647 reported for 2025 was more than what 78% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $397 · 2022: $207 · 2023: $514 · 2024: $896 · 2025: $647.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,959 · Education: $98.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,958.54 |
| Education | $98.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $683.98 | 2023-2025 | Uptravi, Opsumit, Opsynvi |
| Pfizer INC. | $350.48 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $205.48 | 2021-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $162.82 | 2023-2025 | Farxiga, Wainua, Brilinta |
| Boston Scientific Corporation | $139.69 | 2022-2024 | Watchman Flx |
| Philips North America LLC | $121.24 | 2024 | (Cm9) Amb Mon & Diag Und, (Ck4) Mcot |
| Merck Sharp & Dohme LLC | $113.13 | 2021-2024 | Verquvo |
| Novo Nordisk INC | $110.40 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Edwards Lifesciences Corporation | $100.55 | 2024-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Novartis Pharmaceuticals Corporation | $94.84 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.29 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $84.69 | 2022-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $71.47 | 2021-2024 | Camzyos |
| Scpharmaceuticals INC. | $62.76 | 2024-2025 | |
| Irhythm Technologies, INC. | $57.27 | 2022-2024 | Zio Xt Patch, Zio Monitor |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $55.51 | 2021-2025 | Repatha |
| Kiniksa Pharmaceuticals International, Plc | $54.47 | 2024 | Arcalyst |
| Abiomed | $54.38 | 2025 | |
| Alnylam Pharmaceuticals INC. | $18.27 | 2022 | |
| Inspire Medical Systems, INC. | $17.77 | 2025 | Inspire |
| Chiesi USA, INC. | $15.47 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Stern listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.